Prognostic Scores and Survival Rates by Etiology of Hepatocellular Carcinoma: A Review

被引：40

作者：

Calderon-Martinez, Evelyn ^{[1
]}

Landazuri-Navas, Samanta ^{[2
]}

Vilchez, Esmeralda ^{[3
]}

Cantu-Hernandez, Raul ^{[4
]}

Mosquera-Moscoso, Johanna ^{[2
]}

Encalada, Sebastian ^{[2
]}

Al lami, Zahraa ^{[5
]}

Zevallos-Delgado, Christian ^{[6
]}

Cinicola, John ^{[1
]}

机构：

[1] UPMC Harrisburg, Dept Internal Med, Harrisburg, PA 17104 USA

[2] Univ Amer, Dept Internal Med, Quito, Ecuador

[3] Univ Guadalajara, Dept Internal Med, Guadalajara, Jalisco, Mexico

[4] Monterrey Inst Technol & Higher Studies, Dept Internal Med, Monterrey, Nuevo Leon, Mexico

[5] Univ Baghdad, Coll Med, Dept Internal Med, Baghdad, Iraq

[6] Univ Houston, Dept Biomed Engn, Houston, TX USA

来源：

JOURNAL OF CLINICAL MEDICINE RESEARCH-CANADA | 2023年 / 15卷 / 04期

关键词：

Cancer; Hepatocellular; Survival; Mortality; HUMAN-IMMUNODEFICIENCY-VIRUS; STAGING SYSTEMS; HEPATITIS-B; EPIDEMIOLOGY; SURVEILLANCE; CANCER; VALIDATION; MANAGEMENT; NASH;

D O I：

10.14740/jocmr4902

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Hepatocellular carcinoma (HCC) is a common cancer and ranks sixth among all malignancies worldwide. Risk factors for HCC can be classified as infectious or behavioral. Viral hepatitis and alcohol abuse are currently the most common risk factors for HCC; however, non-alcoholic liver disease is expected to become the most common cause of HCC in upcoming years. HCC survival rates vary according to the causative risk factors. As in any malignancy, staging is crucial in making therapeutic decisions. The selection of a specific score should be individualized according to patient characteristics. In this review, we summarize the current data on epidemiology, risk factors, prognostic scores, and survival in HCC.

引用

页码：200 / 207

页数：8

共 68 条

[61] Hepatocellular carcinoma: Impact of academic setting and hospital volume on patient survival [J].

Uhlig, Johannes ;

Sellers, Cortlandt M. ;

Khan, Sajid A. ;

Cha, Charles ;

Kim, Hyun S. .

SURGICAL ONCOLOGY-OXFORD, 2019, 31 :111-118

[62] Epidemiology of hepatocellular carcinoma in Japan [J].

Umemura, Takeji ;

Ichijo, Tetsuya ;

Yoshizawa, Kaname ;

Tanaka, Eiji ;

Kiyosawa, Kendo .

JOURNAL OF GASTROENTEROLOGY, 2009, 44 :102-107

[63] Simplified staging for hepatocellular carcinoma [J].

Vauthey, JN ;

Lauwers, GY ;

Esnaola, NF ;

Do, KA ;

Belghiti, J ;

Mirza, N ;

Curley, SA ;

Ellis, LM ;

Regimbeau, JM ;

Rashid, A ;

Cleary, KR ;

Nagorney, DM .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (06) :1527-1536

[64] Global incidence and mortality of hepatitis B and hepatitis C acute infections, cirrhosis and hepatocellular carcinoma from 2010 to 2019 [J].

Veracruz, Nicolette ;

Gish, Robert G. ;

Cheung, Ramsey ;

Chitnis, Amit S. ;

Wong, Robert J. .

JOURNAL OF VIRAL HEPATITIS, 2022, 29 (05) :352-365

[65] Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 4, pg v238, 2018) [J].

Vogel, A. ;

Cervantes, A. ;

Chau, I. ;

Daniele, B. ;

Llovet, J. M. ;

Meyer, T. ;

Nault, J. -C. ;

Neumann, U. ;

Ricke, J. ;

Sangro, B. ;

Schirmacher, P. ;

Verslype, C. ;

Zech, C. J. ;

Arnold, D. ;

Martinelli, E. .

ANNALS OF ONCOLOGY, 2022, 33 (06) :666-666

[66] Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Vogel, A. ;

Cervantes, A. ;

Chau, I. ;

Daniele, B. ;

Llovet, J. ;

Meyer, T. ;

Nault, J. -C. ;

Neumann, U. ;

Ricke, J. ;

Sangro, B. ;

Schirmacher, P. ;

Verslype, C. ;

Zech, C. J. ;

Arnold, D. ;

Martinelli, E. .

ANNALS OF ONCOLOGY, 2018, 29 :238-255

[67] An overview of the healthcare system in Taiwan [J].

Wu, Tai-Yin ;

Majeed, Azeem ;

Kuo, Ken N. .

LONDON JOURNAL OF PRIMARY CARE, 2010, 3 (02) :115-119

[68] Insulin Resistance, Obesity and Lipotoxicity [J].

Yazici, Dilek ;

Sezer, Havva .

OBESITY AND LIPOTOXICITY, 2017, 960 :277-304

← 1 2 3 4 5 6 7 →